Cartesian Therapeutics (RNAC) Goodwill & Intangibles (2023 - 2026)

Cartesian Therapeutics (RNAC) has 4 years of Goodwill & Intangibles data on file, last reported at $142.1 million in Q1 2026.

• Goodwill & Intangibles for Q1 2026 came in at $142.1 million, down 28.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $142.1 million (down 28.53% YoY), and the FY2025 annual result was $142.1 million, down 28.53% from the prior year.
• Goodwill & Intangibles held at $142.1 million in Q1 2026 per RNAC's latest filing, from $142.1 million in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $198.8 million in Q4 2023 and troughed at $142.1 million in Q4 2025.
• A 4-year average of $187.4 million and a median of $198.8 million in 2023 frame the typical range for Goodwill & Intangibles.
• The sharpest annual moves came in 2024 and 2025: Goodwill & Intangibles changed 0.0% in 2024, then slipped 28.53% in 2025.
• A 4-year view of Goodwill & Intangibles shows it stood at $198.8 million in 2023, then changed by 0.0% to $198.8 million in 2024, then fell by 28.53% to $142.1 million in 2025, then changed by 0.0% to $142.1 million in 2026.
• Business Quant data shows RNAC's Goodwill & Intangibles at $142.1 million in Q1 2026, $142.1 million in Q4 2025, and $198.8 million in Q3 2025.